Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
Retatrutide is an investigational triple-agonist peptide currently under development by Eli Lilly and Company as a potential treatment for obesity and type 2 diabetes. Unlike existing therapies that target one or two receptors, Retatrutide uniquely activates three key metabolic pathways: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This multi-target approach aims to maximize weight loss while improving glycemic control through synergistic mechanisms. The molecule enhances insulin secretion in response to meals, suppresses appetite by acting on central nervous system centers, and increases energy expenditure via glucagon-mediated lipolysis and thermogenesis.
Although specific structural data such as the exact molecular formula and CAS number are proprietary and not always publicly disclosed in standard chemical databases due to its status as a clinical candidate, Retatrutide is chemically defined as a modified peptide consisting of 38 amino acids with specific fatty acid side chains designed to prolong its half-life. It is typically administered via subcutaneous injection once weekly. Clinical trials have demonstrated remarkable efficacy, with some participants achieving significant reductions in body weight exceeding 20% over several months, surpassing outcomes seen with dual agonists like tirzepatide.
The primary intended use of Retatrutide is to address the global obesity epidemic by providing a more potent therapeutic option for patients who have not responded adequately to single or dual receptor agonists. Beyond weight reduction, it offers substantial benefits for cardiovascular health, including improvements in blood pressure, lipid profiles, and markers of liver fat accumulation associated with non-alcoholic steatohepatitis (NASH). While promising, the drug remains in various phases of clinical evaluation to fully establish its long-term safety profile, particularly regarding potential gastrointestinal side effects and thyroid C-cell tumor risks observed in animal studies. As research progresses, Retatrutide represents a paradigm shift in metabolic medicine, offering hope for comprehensive management of complex metabolic disorders through a single, highly effective agent.